Immunocore is a pioneering clinical-stage T cell receptor biotechnology company working to develop and commercialise a new generation of transformative medicines to address unmet needs in cancer, infection and autoimmune disease

 

Background

  • Lead compound tebentafusp in pivotal clinical studies as a monotherapy for patients with metastatic melanoma
  • Bill and Melinda Gates Foundation investment of $40 million for collaboration in infectious diseases in 2016
  • Europe’s largest ever private financing round in biotech with a raise of $320 million in 2015, followed by a $130 million Series B financing in 2020

$320m

Europe’s largest ever private financing round in biotech

 

Our strategy

  • Detailed review and overhaul of all corporate materials, including key messages and creation of a corporate video ahead of Series A financing
  • Extensive programme of media introductions for senior management in the lead up to major announcements, ensuring that key journalists knew the Company well
  • Communicating Immunocore’s scientific story more broadly, including compelling single-agent efficacy of tebentafusp in a solid, ‘cold’, low mutation tumour
  • Onboarding of new CEO, Bahija Jallal, in 2019
  • Communications around Series B financing in 2020
  • Support with ongoing launch preparations for tebentefusp

 

Outcome

  • Significant worldwide coverage around major newsflow in publications including Financial Times, WSJ, New York Times, BBC (broadcast), newswires and international trade press
  • Momentum continued with ongoing interest in Immunocore’s scientific programme and widespread coverage of corporate development and data in the lead up to commercialisation